



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/772,963	02/05/2004	David P. Bingaman	2471 US	5299

7590 06/15/2005
Teresa J. Schultz
Alcon Research, Ltd.
6201 South Freeway, Q-148
Fort Worth, TX 76124-2099

EXAMINER

HUI, SAN MING R

ART UNIT PAPER NUMBER

1617

DATE MAILED: 06/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/772,963	Applicant(s) BINGAMAN ET AL.	
	Examiner San-ming Hui	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 March 2005.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 1-18 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>2-3-05</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's amendments filed March 9, 2005 have been entered. The addition of claims 3-18 is acknowledged. Claims 1-18 are pending.

The outstanding rejection under 35 USC 102(b) is withdrawn in view of the applicant's remarks that anecortave acetate is not a glucocorticoid.

The outstanding double patenting rejection is also withdrawn in view of the fact that anecortave acetate is not a glucocorticoid.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-5 and 8-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Peyman et al. (US patent 5,516,522) and Clark, Clark is reference of record.

Peyman teaches prednisolone, prednisolone acetate, triamcinolone, fluoromethalone, and fluoromethalone acetate as useful in treating proliferative vitreoretinopathy (PVR), an ocular angiogenesis-associated disorder (See col. 7, lines 33-55, especially lines 50, 51, 54). Peyman also teaches the ocular formulation may be as intraocular implant (See the abstract and claim 1).

Clark teaches anecortave acetate as useful in treating ocular neovascularization condition (See claims 1-5). Clark also teaches the composition can be formulated and administered as intraocular injection (See col. 4, lines 50).

The references taken together do not expressly teach the incorporation of both the herein claimed steroids and anecortave acetate together in a method of treating angiogenesis disorder such as PVR. The references taken together do not expressly teach the herein claimed dosages.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate the herein claimed steroids and anecortave acetate together in a method of treating angiogenesis disorder such as PVR. It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ the herein claimed dosage to treat PVR.

One of ordinary skill in the art would have been motivated to incorporate the herein claimed steroids and anecortave acetate together in a method of treating angiogenesis disorder such as PVR since the agents are well-known to be useful in treating PVR or neovascularization individually. Therefore, concomitantly employing both agents in a method for the same indications would be *prima facie* obvious (See *In re Kerkhoven* 205 USPQ 1069).

Furthermore, one of ordinary skill in the art would have been motivated to employ the herein claimed dosage to treat PVR since the optimization of result effect parameters (dosage range, dosing regimens) is obvious as being within the skill of the artisan.

Claims 1-2, 4-5, and 16-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO95/03807('807) and Clark.

'807 teaches a method of treating neovascular macular degeneration, an ocular angiogenesis disorder, by administration of triamcinolone (See the abstract, claims 22-25). '807 teaches the routes of administration may be intravitreal injection (See page 3, lines 19-25).

Clark teaches anecortave acetate as useful in treating ocular neovascularization condition (See claims 1-5). Clark also teaches the composition can be formulated and administered as intraocular injection (See col. 4, lines 50).

The references taken together do not expressly teach the incorporation of both the triamcinolone and anecortave acetate together in a method of treating angiogenesis disorder such as neovascular macular degeneration. The references taken together do not expressly teach the herein claimed dosages.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate triamcinolone and anecortave acetate together in a method of treating angiogenesis disorder such as neovascular macular degeneration. It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ the herein claimed dosage to treat neovascular macular degeneration.

One of ordinary skill in the art would have been motivated to incorporate triamcinolone and anecortave acetate together in a method of treating angiogenesis disorder such as neovascular macular degeneration since the agents are well-known to

Art Unit: 1617

be useful in treating neovascular macular degeneration individually. Therefore, concomitantly employing both agents in a method for the same indications would be *prima facie* obvious (See *In re Kerkhoven* 205 USPQ 1069).

Furthermore, one of ordinary skill in the art would have been motivated to employ the herein claimed dosage to treat neovascular macular degeneration since the optimization of result effect parameters (dosage range, dosing regimens) is obvious as being within the skill of the artisan.

Claims 1-3 and 6-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Clark and US 4,686,214 ('214).

Clark teaches anecortave acetate as useful in treating ocular neovascularization inflammatory condition (See claims 1-5). Clark also teaches the composition can be formulated and administered as intraocular injection (See col. 4, lines 50).

'214 teaches rimexolone as useful in treating ocular inflammation (See claim 2). The effective dosage of rimexolone taught as 0.05 to 2.0% (See col. 2, line 59-60).

The references taken together do not expressly teach the incorporation of both rimexolone and anecortave acetate together in a method of treating angiogenesis inflammatory disorder. The references taken together do not expressly teach the herein claimed dosages.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to the incorporation of both rimexolone and anecortave acetate together in a method of treating angiogenesis inflammatory disorder. It would have

Art Unit: 1617

been obvious to one of ordinary skill in the art at the time the invention was made to employ the herein claimed dosage to treat angiogenesis inflammatory disorder.

One of ordinary skill in the art would have been motivated to the incorporation of both rimexolone and anecortave acetate together in a method of treating angiogenesis inflammatory disorder since the agents are well-known to be useful in treating ocular inflammation individually. Therefore, concomitantly employing both agents in a method for treating ocular inflammation associated with angiogenesis would be *prima facie* obvious (See *In re Kerkhoven* 205 USPQ 1069).

Furthermore, one of ordinary skill in the art would have been motivated to employ the herein claimed dosage to treat ocular inflammation associated with angiogenesis since the optimization of result effect parameters (dosage range, dosing regimens) is obvious as being within the skill of the artisan.

Response to Arguments

Applicant's arguments with respect to claims 1-18 have been considered but are moot in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax

Art Unit: 1617

phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


San-ming Hui
Primary Examiner
Art Unit 1617